Vasomotor symptoms are a frequent adverse effect of estrogen deprivation. Hormone replacement therapy is not an ideal option for breast cancer patients. Non-pharmacologic measures may be enough to control mild vasomotor symptoms. SSRI/SNRI or anticonvulsants should be first-line in moderate-to-severe symptoms. In women taking tamoxifen, potent CYP2D6 inhibitors should be avoided.